Back to News
Market Impact: 0.15

Detailed Fundamental Analysis

SPYVNDAQ
Company FundamentalsAnalyst InsightsDerivatives & VolatilityHealthcare & Biotech
Detailed Fundamental Analysis

Validea's fundamental report on the SPDR Portfolio S&P 500 Value ETF (SPYV) identifies it as a Large-Cap Low Volatility ETF, notably scoring 85 out of 99 for low volatility exposure. The ETF also exhibits a moderate value factor score of 62 and lower momentum at 33. Its portfolio is primarily concentrated in the Financial sector and the Biotechnology & Drugs industry, providing institutional investors with a clear profile of its factor tilts and sector exposure.

Analysis

According to Validea's fundamental report, the SPDR Portfolio S&P 500 Value ETF (SPYV) is structured as a Large-Cap Low Volatility fund with a distinct factor profile. The ETF exhibits a pronounced defensive characteristic, evidenced by its very high low-volatility score of 85 out of 99. Its exposure to the value factor is moderate, with a score of 62, while its quality score of 53 indicates a neutral or market-average exposure to companies with strong balance sheets. Notably, SPYV has a low momentum score of 33, suggesting the underlying portfolio is not positioned to capture stocks with recent strong price appreciation. The fund's composition is heavily weighted towards the Financial sector, and its largest single industry exposure is in Biotechnology & Drugs, defining its specific risk and return drivers.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

NDAQ0.00
SPYV0.00

Key Decisions for Investors

  • Investors seeking to de-risk their equity exposure or add a defensive component to their portfolio should consider SPYV, given its high low-volatility score of 85.
  • Be aware that the ETF's low momentum score of 33 indicates it is likely to underperform the broader market during strong, momentum-driven rallies.
  • The significant portfolio concentration in the Financial and Biotechnology & Drugs sectors requires investors to assess potential overweighting risks relative to their existing holdings.